The diminished pipeline for medications to treat mental health and substance use disorders

Psychiatric Services

Volumn 65, Issue 12, 2014, Pages 1433-1438

  O'Brien, Peggy L ^a   Thomas, Cindy Parks ^a   Hodgkin, Dominic ^a   Levit, Katharine R ^b   Mark, Tami L ^b  

^a BRANDEIS UNIVERSITY   (United States)

^b IBM WATSON HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITIFADINE; ARIPIPRAZOLE; BITOPERTIN; COCAINE; ENCENICLINE; ESTRADIOL; KETAMINE; LISDEXAMFETAMINE; LURASIDONE; MINOCYCLINE; PSYCHOTROPIC AGENT; TOPIRAMATE;

ALCOHOL USE DISORDER; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG ABUSE; DRUG APPROVAL; DRUG DEPENDENCE TREATMENT; HUMAN; INSOMNIA; INTERVIEW; MENTAL DISEASE; MOOD DISORDER; NEGATIVE SYNDROME; NONHUMAN; OFF LABEL DRUG USE; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; SUBSTANCE USE; TOBACCO DEPENDENCE; DRUG DEVELOPMENT; EXPERIMENTAL THERAPY; MENTAL DISORDERS; MENTAL HEALTH; PROCEDURES;

CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; MENTAL HEALTH; PSYCHOTROPIC DRUGS; THERAPIES, INVESTIGATIONAL;

EID: 84913592382     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201400044     Document Type: Article

References (57)

1. Blanco C, Xu Y, Brady K, et al: Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from National Epidemiological Survey on Alcohol and Related Conditions. Drug and Alcohol Dependence 132:630-638, 2013
2. Kessler RC, Chiu WT, Demler O, et al: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62:617-627, 2005
3. The Numbers Count: Mental Disorders in America. Rockville, Md, National Institute of Mental Health. Available at www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america/index.shtml#Intro. Accessed May 26, 2013
4. Pastor PN, Reuben CA: Diagnosed Attention Deficit Hyperactivity Disorder and Learning Disability: United States, 2004-2006. Hyattsville, Md, Centers for Disease Control and Prevention, National Center for Health Statistics, 2008
5. Insel TR: Assessing the economic costs of serious mental illness. American Journal of Psychiatry 165:663-665, 2008
6. Miller TR, Hendrie D: Substance Abuse Prevention Dollars and Cents: A Cost-Benefit Analysis. DHHS pub no (SMA) 07-4298. Rockville, Md, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, 2008
7. Harwood HJ: Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods, and Data. Bethesda, Md, National Institute on Alcohol Abuse and Alcoholism, 2000
8. Harwood HJ, Bouchery E: The Economic Costs of Drug Abuse in the United States, 1992-1998. Washington, DC, Office of National Drug Control Policy, 2004
9. Murrough JW, Charney DS: Is there anything really novel on the antidepressant horizon? Current Psychiatry Reports 14:643-649, 2012
10. Ibrahim HM, Tamminga CA: Treating impaired cognition in schizophrenia. Current Pharmaceutical Biotechnology 13:1587-1594, 2012
11. Miyamoto S, Miyake N, Jarskog LF, et al: Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry 17:1206-1227, 2012
12. Moghaddam B, Javitt D: From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37:4-15, 2012
13. Adams CP, Brantner VV: Spending on new drug development. Health Economics 19:130-141, 2010
14. Lesney MS: What about the FDA? Modern Drug Discovery 3:29-33, 2000. Available at pubs.acs.org/subscribe/archive/mdd/v03/i08/html/10clinical.html
15. The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective. Silver Spring, Md, US Food and Drug Administration, 2013. Available at www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm. Accessed May 31, 2013
16. Medicines in Development: Mental Illness. Washington, DC, Pharmaceutical Research and Manufacturers of America, 2012. Available at www.phrma.org/sites/default/files/pdf/phrmamedsindevmentalillness2012.pdf
17. Vernon JA, Golec JH, Dimasi JA: Drug development costs when financial risk is measured using the Fama-French three-factor model. Health Economics 19:1002-1005, 2010
18. Frequently Asked Questions on Patents and Exclusivity. Silver Spring, Md, US Food and Drug Administration. Available at www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm. Accessed Dec 5, 2012
19. Small Business Assistance: Frequently Asked Questions for New Drug Product Exclusivity. Silver Spring, Md, US Food and Drug Administration. Available at www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm069962.htm. Accessed May 31, 2013
20. Aitken ML, Berndt ER, Bosworth B, et al: The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity. NBER working paper 19487. Cambridge, Mass, National Bureau of Economic Research, 2013. Available at www.nber.org/papers/w19487.pdf
21. Hemphill CS, Sampat BN: Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics 31:327-339, 2012
22. Thomas JR: Pharmaceutical Patent Litigation Settlements: Implications for Competition and Innovation. US Congressional Research Service, Jan 6, 2010. Available at scholarship.law.georgetown.edu/facpub/574
23. Kesselheim AS, Avorn J: Biomedical patents and the public's health: is there a role for eminent domain? JAMA 295:434-437, 2006
24. The Biopharmaceutical Pipeline: Evolving Science, Hope for Patients. Washington, DC, Pharmaceutical Research and Manufacturers of America, 2013. Available at www.phrma.org/sites/default/files/pdf/phrmapipelinereportfinal11713.pdf
25. Hyman SE: Revolution stalled. Science Translational Medicine, 2012 (doi 10.1126/scitranslmed.3003142)
26. Insel TR: Next-generation treatments for mental disorders. Science Translational Medicine, 2012 (doi 10.1126/scitranslmed.3004873)
27. Sanders L: No new meds. Science News 183:26-29, 2013
28. Friedman RA: A dry pipeline for psychiatric drugs. New York Times, Aug 19, 2013
29. Berk M: Pathways to new drug discovery in neuropsychiatry. BMC Medicine 10:151, 2012
30. Li X, Frye MA, Shelton RC: Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 37:77-101, 2012
31. Philip NS, Carpenter LL, Tyrka AR, et al: The nicotinic acetylcholine receptor as a target for antidepressant drug development. ScientificWorldJournal, 2012 (doi 10.1100/2012/104105)
32. Goff DC, Hill M, Barch D: The treatment of cognitive impairment in schizophrenia. Pharmacology, Biochemistry, and Behavior 99:245-253, 2011
33. Kantrowitz J, Javitt DC: Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Current Opinion in Psychiatry 25:96-102, 2012
34. Huskamp HA, Busch AB, Domino ME, et al: Antidepressant reformulations: who uses them, and what are the benefits? Health Affairs 28:734-745, 2009
35. Overview. Bethesda, Md, National Institute of Mental Health, Division of Adult Translational Research and Treatment Development. Available at www.nimh.nih.gov/about/organization/datr/index.shtml. Accessed Dec 10, 2013
36. Rorick-Kehn LM, Johnson BG, Knitowski KM, et al: In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193:121-136, 2007
37. Litten RZ, Egli M, Heilig M, et al: Medications development to treat alcohol dependence: a vision for the next decade. Addiction Biology 17:513-527, 2012
38. Vaughn P: NIH funding boosts new Alzheimer's research on prevention, novel drug targets. Bethesda, Md, National Institute on Aging, Sept 18, 2013. Available at www.nia.nih.gov/newsroom/2013/09/nih-funding-boosts-new-alzheimers-research-prevention-novel-drug-targets#.UlQXpxAqOxg
39. Cancer Research Funding. Bethesda, Md, National Cancer Institute. Available at www.cancer.gov/cancertopics/factsheet/NCI/research-funding. Accessed July 21, 2014
40. NAID ' s List of Foundations and Other Funding Sources. Bethesda, Md, National Institute of Allergy and Infectious Diseases. Available at www.niaid.nih.gov/researchfunding/ann/pages/found.aspx#Gates. Accessed July 21, 2014
41. Berndt ER, Cockburn IM, Grépin KA: The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications. PharmacoEconomics 24(suppl 2):69-86, 2006
42. Health, United States, 2011, With Special Feature on Socioeconomic Status and Health. DHHS pub no 2012-1232. Hyattsville, Md, National Center for Health Statistics, 2012
43. Rattinger GB, Burcu M, Dutcher SK, et al: Pharmacotherapeutic management of dementia across settings of care. Journal of the American Geriatrics Society 61:723-733, 2013
44. Vincent GK, Velkoff VA: The Next Four Decades: The Older Population in the United States: 2010 to 2050. Washington, DC, US Census Bureau, 2010
45. Comer JS, Olfson M, Mojtabai R: National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. Journal of the American Academy of Child and Adolescent Psychiatry 49:1001-1010, 2010
46. Merikangas KR, He JP, Rapoport J, et al: Medication use in US youth with mental disorders. JAMA Pediatrics 167:141-148, 2013
47. Olfson M, He JP, Merikangas KR: Psychotropic medication treatment of adolescents: results from the National Comorbidity Survey-Adolescent Supplement. Journal of the American Academy of Child and Adolescent Psychiatry 52:378-388, 2013
48. Collins SR, Robertson R, Garber T, et al: Insuring the Future: Current Trends in Health Coverage and the Effects of Implementing the Affordable Care Act. New York, Commonwealth Fund, 2013
49. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. Silver Spring, Md, US Food and Drug Administration. Available at www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm. Accessed July 21, 2014
50. Albright B: Three key antipsychotics lose patent protection. Behavioral Healthcare, Nov 16, 2011. Available at www.behavioral.net/article/three-key-antipsychotics-lose-patent-protection
51. Davis JC, Furstenthal L, Desai AA, et al: The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nature Reviews Drug Discovery 8:279-286, 2009
52. Harrison PJ: The current and potential impact of genetics and genomics on neuropsychopharmacology. European Neuropsychopharmacology (Epub ahead of print, March 25, 2013). Available at www.europeanneuropsychopharmacology.com/article/S0924-977X(13)00071-0/abstract
53. Institute of Medicine: Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, DC, National Academies Press, 2013
54. D'Souza DC, Radhakrishnan R, Perry E, et al: Feasibility, safety, and efficacy of the combination of d-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology 38:492-503, 2013
55. Morel CM, Mossialos E: Stoking the antibiotic pipeline. BMJ 340:c2115, 2010
56. Hecht R, Wilson P, Palriwala A: Improving health R&D financing for developing countries: a menu of innovative policy options. Health Affairs 28:974-985, 2009
57. Honig PK: Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology. Clinical Pharmacology and Therapeutics 89:151-156, 2011